Immunoassays

Wednesday, 08 April, 2009 | Supplied by: Merck Pty Ltd


Novagen has introduced multiplex immunoassays for the bead-based Luminex xMAP Technology platform. The range of immuno-assays allows the multiplex quantification of phosphorylated proteins, giving researchers the opportunity to examine changes in cellular signalling that reflect disease states or various drug treatments.

The WideScreen EpiTag assays detect key signalling events in the ERK pathway from both human and mouse samples.

WideScreen RTK assays allow the simultaneous determination of tyrosine phosphorylation status of several key receptor tyrosine kinases.

The WideScreen Human Cancer Panel 1 provides the quantitative detection of six cancer-associated proteins found in biological fluids.

The WideScreen Human Cancer Panel provides quantitative detection of 12 human growth factors found in biological fluids.

The WideScreen Human Cardiovascular Disease Panel 1 provides quantitative detection of seven human apolipoproteins.

Finally, the WideScreen Human Cardiovascular Disease Panel 2 provides quantitative detection of six human cytokines/chemokines associated with cardiovascular disease.

Online: www.sigmaaldrich.com/AU/en
Phone: 1800 800 097
Related Products

Cayman Chemical Cellular Metabolism Screening Library

Cayman Chemical's Cellular Metabolism Screening Library consists of two plates and contains...

Navinci Diagnostics NaveniFlex Cell Red proximity ligation assay kit

Optimised for cell samples, the kit enables fluorescence visualisation of protein–protein...

Lonza TheraPEAK AmpliCell Cytokines and TheraPEAK 293-GT Medium

The products provide researchers and manufacturers with high-performance, scalable and...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd